Fundraising Fox

Coya Therapeutics

NASDAQ: COYA

Houston, US · Founded 2020 · Delaware corporation · 1 known investors

Founders & leadership

DS
David SnyderinExecutive
FG
Fred GrossmanExecutive
HB
Howard BermanExecutive
AG
Andrea GoldsteinNamed on SEC filing
JT
Jani TuomiNamed on SEC filing
SM
Shawn M. TitcombNamed on SEC filing

Board

DG
Dov GoldsteininBoard director
WR
Wilbur RossBoard director
HG
Hideki GarrenBoard director
AV
Anabella VillalobosinBoard director
DW
Dieter WeinandBoard director
AL
Ann LeeinBoard director

Investors · 1

Reported raises · per SEC filings

Form D private placements

$56.9M disclosed across 4 of 7 rounds · 2020–2026

$10MraisedOct 2024 · 9 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David SnyderExecutive Officer
  • Hideki GarrenDirector
  • Anabella VillalobosDirector
  • Dieter WeinandDirector
  • Ann LeeDirector
  • Fred GrossmanExecutive Officer
  • Dov GoldsteinDirector
  • Wilbur RossDirector
  • Howard BermanExecutive Officer, Director
  • Arun SwaminathanDirector
Offering amount
$10M
Amount sold
$10M
Sales commissions
$700K
Placement agents
Wilmington Capital Securities, LLC, Chardan Capital Markets LLC, BTIG, LLC
First sale
Oct 2024
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$26.5MraisedDec 2023 · 122 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Dieter WeinandDirector
  • Ann LeeDirector
  • Wilbur RossDirector
  • Fred GrossmanExecutive Officer
  • Howard BermanExecutive Officer, Director
  • Hideki GarrenDirector
  • Dov GoldsteinDirector
  • Anabella VillalobosDirector
  • David SnyderExecutive Officer
Offering amount
$26.5M
Amount sold
$26.5M
Placement agents
BTIG, LLC, Newbridge Securities Corporation
First sale
Dec 2023
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$10.4MraisedMay 2022 · 45 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • David SnyderExecutive Officer
  • Anabella VillalobosDirector
  • Dov GoldsteinDirector
  • Adrian HepnerExecutive Officer
  • Ann LeeDirector
  • Howard BermanExecutive Officer, Director
  • Hideki GarrenDirector
  • Greg MacMichaelExecutive Officer
Offering amount
$20M
Amount sold
$10.4M
Sales commissions
$1.4M
Placement agents
Wilmington Capital Securities, LLC
First sale
Apr 2022
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗
$10MraisedJan 2021 · 57 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Howard BermanExecutive Officer, Director
  • Andrea GoldsteinExecutive Officer, Director
  • Jani TuomiDirector
  • Shawn M. TitcombDirector
Offering amount
$10M
Amount sold
$10M
Sales commissions
$700K
Placement agents
Shawn M. Titcomb
First sale
Dec 2020
Incorporated
Corporation, Delaware, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap

Companies competing with Coya Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Frequently asked questions

Who are Coya Therapeutics's investors?
Coya Therapeutics's investors include Checkmate Capital Group LLC.
How much funding has Coya Therapeutics raised?
Coya Therapeutics has disclosed $56.9M raised across 4 of its 7 known rounds.
Where is Coya Therapeutics headquartered?
Coya Therapeutics is headquartered in Houston, US.